Cytokine‑Driven Modulation of Immune Checkpoint Therapy Response in Colorectal Cancer.
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape for a subset of patients with colorectal cancer (CRC), particularly those with mismatch repair‑deficient/microsatellite‑instability-high (dMMR/MSI‑H) subtype. Nevertheless, most CRCs with mismatch repair‑proficient (pMMR)/microsatellite‑stab...